Predict your next investment

Asset/Investment Management

See what CB Insights has to offer

Investments

25

Portfolio Exits

7

About Avidity Partners

Avidity Partners is an investment firm based in Dallas, Texas.

Avidity Partners Headquarter Location

Dallas, Texas,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Avidity Partners News

AN2 Therapeutics Closes $80M Series B Financing

Jan 7, 2022

AN2 Therapeutics, Inc. , a Menlo Park, CA-based clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, completed an $80m Series B redeemable convertible preferred stock financing. The round was led by RA Capital Management, and included BVF Partners L.P., Surveyor Capital (a Citadel company), Avidity Partners, Monashee Investment Management, and Hatteras Venture Partners, who joined existing investors to complete this round. The financing is expected to support advancement of AN2’s development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). Led by Eric Easom, President and Chief Executive Officer, AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. The company is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). In addition, AN2 Therapeutics also appointed two additional members to its Board of Directors, Patricia Martin and Stephanie Wong. Ms. Martin has over 25 years of biopharmaceutical leadership experience across multiple therapeutic areas and disciplines. A former Eli Lilly and Company executive, Ms. Martin was the Chief Operating Officer of Lilly Diabetes as well as Lilly’s corporate Chief Diversity Officer and Chief Alliance Officer. During her career at Lilly, she also held leadership roles in strategy, finance, clinical product development, human resources, and investor relations. Since 2019, Ms. Martin has served as the President and CEO of BioCrossroads, where she is focused on growing Indiana’s life sciences sector, through research and education, seed funds, and economic development. Ms. Martin received a B.S. in Accounting from Indiana University, an M.B.A. from Harvard Business School, and is a Certified Public Accountant (inactive) in the State of Arizona. Ms. Wong has over 20 years of finance and accounting experience in public and private companies within the biotechnology industry. Currently, Ms. Wong serves as Chief Financial Officer and Secretary of Calithera Biosciences (NASDAQ: CALA). Prior to joining Calithera, Ms. Wong served as Vice President, Finance and Controller at SciClone Pharmaceuticals and in senior finance roles at AcelRx Pharmaceuticals and Kosan Biosciences. Ms. Wong received a B.S. in Business Administration from the University of California, Berkeley and is a Certified Public Accountant (inactive) in the State of California. FinSMEs 07/01/2022

Avidity Partners Investments

25 Investments

Avidity Partners has made 25 investments. Their latest investment was in AN2 Therapeutics as part of their Series B on January 1, 2022.

CBI Logo

Avidity Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/7/2022

Series B

AN2 Therapeutics

$80M

Yes

1

12/15/2021

Series E

Innovaccer

$150M

Yes

6

12/8/2021

Unattributed VC

ConnectRN

$76M

Yes

4

11/9/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/6/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

12/15/2021

12/8/2021

11/9/2021

10/6/2021

Round

Series B

Series E

Unattributed VC

Series B

Series B

Company

AN2 Therapeutics

Innovaccer

ConnectRN

Subscribe to see more

Subscribe to see more

Amount

$80M

$150M

$76M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

6

4

10

10

Avidity Partners Portfolio Exits

7 Portfolio Exits

Avidity Partners has 7 portfolio exits. Their latest portfolio exit was Amunix on December 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/21/2021

Acquired

$99M

10

7/23/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/21/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/18/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/9/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/21/2021

7/23/2021

6/21/2021

6/18/2021

10/9/2020

Exit

Acquired

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

10

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.